Subscribe To
Immunovant announces proposed offering of $300 million of common stock
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives ...
September 26, 2023, 9:00 pm
Roivant stock could go higher on monetization potential of ‘blockbuster' assets
Roivant shares finished more than 20% higher on Tuesday after Immunovant, in which Roivant holds a 56.5% stake, released positive data from an early-s...
September 26, 2023, 4:59 pm
Immunovant shares skyrocket after trial of its autoimmune drug beats expectations
Immunovant (IMVT) shares virtually doubled on Tuesday after the biopharmaceutical company reported positive results from a Phase 1 trial of its experi...
September 26, 2023, 4:20 pm
Intercept pharmaceuticals stock soars on alfasigma acquisition deal
Intercept Pharmaceuticals (NASDAQ:ICPT) Inc shares surged 79% to $18.64 in late-morning trading on Tuesday after the biopharmaceutical company specia...
September 26, 2023, 11:42 am
Immunovant and roivant jump as new drug shapes up to become blockbuster
There was a bumper boost for stock in two Nasdaq-listed biotechs premarket after an experimental antibody treatment was revealed to have blockbuster p...
September 26, 2023, 9:28 am
Immunovant to host conference call and webcast to report initial imvt-1402 phase 1 results on september 26, 2023
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives ...
September 26, 2023, 3:01 am
Immunovant to host conference call and webcast to report initial imvt-1402 phase 1 results on september 26, 2023
NEW YORK, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives f...
September 25, 2023, 11:01 pm
Week in review: everest acquires novel autoimmune therapy in $132 million agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from ...
September 24, 2023, 10:33 pm
autoimmune disease diagnostics market surges at 3.8% cagr from 2019 to 2027 fueled by heightened public awareness: tmr report
The application of AI in healthcare, particularly in analyzing medical images and patient data, can lead to more accurate and efficient ...
September 22, 2023, 2:36 pm
Why shares of calliditas therapeutics are rising thursday
Calliditas' lead therapy is Tarpeyo, which has accelerated approval from the FDA to fight a rare autoimmune...
September 21, 2023, 2:32 pm
Annexon biosciences to participate in the 2023 cantor global healthcare conference
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class o...
September 19, 2023, 6:30 am
Cabaletta bio: how long can unique cell therapy developer's sensational bull run continue?
Cabaletta Bio stock has experienced a significant bull run, rising over 2,100% in the past year. The company's focus on ...
September 19, 2023, 4:56 am
Why aurinia pharmaceuticals stock is slumping today
Aurinia Pharmaceuticals, an autoimmune disease specialist, is trading lower on high volume today. The b...
September 18, 2023, 2:18 pm
Ispecimen expands provider network to enhance support for women’s health research
Additional Providers Increase Biospecimen Access for Researchers Focused on Cervical, Uterine and Breast Cancers, as well as Reproductive Health, Card...
September 13, 2023, 11:30 am
Gri bio to present at the h.c. wainwright 25th annual global investment conference
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing a...
September 6, 2023, 9:05 am
Globally recognized expert in rare neurologic diseases, dr. michael levy, joins trethera scientific advisory board
LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) — Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs ...
September 5, 2023, 2:55 pm
Fate therapeutics to present at upcoming september investor conferences
SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage b...
August 31, 2023, 8:00 am
Cabaletta bio to participate in multiple upcoming investor conferences in september
PHILADELPHIA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and l...
August 30, 2023, 8:00 am
Argenx to present at upcoming investor conferences
August 30 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of pe...
August 30, 2023, 1:00 am
Apogee therapeutics: potential to target autoimmune disorders with less frequent dosing
Review of Apogee Therapeutics' safety and pharmacokinetic data from phase 1 study using APG777 in healthy volunteers expected in mid-2024. Pending pos...
August 22, 2023, 8:14 am